Literature DB >> 34819673

Mechanism for the activation of the anaplastic lymphoma kinase receptor.

Andrey V Reshetnyak1, Paolo Rossi1, Alexander G Myasnikov1, Munia Sowaileh1, Jyotidarsini Mohanty2, Amanda Nourse1, Darcie J Miller1, Irit Lax2, Joseph Schlessinger3, Charalampos G Kalodimos4.   

Abstract

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) that regulates important functions in the central nervous system1,2. The ALK gene is a hotspot for chromosomal translocation events that result in several fusion proteins that cause a variety of human malignancies3. Somatic and germline gain-of-function mutations in ALK were identified in paediatric neuroblastoma4-7. ALK is composed of an extracellular region (ECR), a single transmembrane helix and an intracellular tyrosine kinase domain8,9. ALK is activated by the binding of ALKAL1 and ALKAL2 ligands10-14 to its ECR, but the lack of structural information for the ALK-ECR or for ALKAL ligands has limited our understanding of ALK activation. Here we used cryo-electron microscopy, nuclear magnetic resonance and X-ray crystallography to determine the atomic details of human ALK dimerization and activation by ALKAL1 and ALKAL2. Our data reveal a mechanism of RTK activation that allows dimerization by either dimeric (ALKAL2) or monomeric (ALKAL1) ligands. This mechanism is underpinned by an unusual architecture of the receptor-ligand complex. The ALK-ECR undergoes a pronounced ligand-induced rearrangement and adopts an orientation parallel to the membrane surface. This orientation is further stabilized by an interaction between the ligand and the membrane. Our findings highlight the diversity in RTK oligomerization and activation mechanisms.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34819673      PMCID: PMC8639797          DOI: 10.1038/s41586-021-04140-8

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   69.504


  55 in total

1.  ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)

Authors:  S W Morris; C Naeve; P Mathew; P L James; M N Kirstein; X Cui; D P Witte
Journal:  Oncogene       Date:  1997-05-08       Impact factor: 9.867

2.  Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome.

Authors:  Hongbing Zhang; Lily I Pao; Aileen Zhou; Arthur D Brace; Robert Halenbeck; Amy W Hsu; Thomas L Bray; Kevin Hestir; Elizabeth Bosch; Ernestine Lee; Gang Wang; Haixia Liu; Brian R Wong; W Michael Kavanaugh; Lewis T Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-20       Impact factor: 11.205

Review 3.  Cell signaling by receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

4.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

5.  Oncogenic mutations of ALK kinase in neuroblastoma.

Authors:  Yuyan Chen; Junko Takita; Young Lim Choi; Motohiro Kato; Miki Ohira; Masashi Sanada; Lili Wang; Manabu Soda; Akira Kikuchi; Takashi Igarashi; Akira Nakagawara; Yasuhide Hayashi; Hiroyuki Mano; Seishi Ogawa
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

6.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.

Authors:  Isabelle Janoueix-Lerosey; Delphine Lequin; Laurence Brugières; Agnès Ribeiro; Loïc de Pontual; Valérie Combaret; Virginie Raynal; Alain Puisieux; Gudrun Schleiermacher; Gaëlle Pierron; Dominique Valteau-Couanet; Thierry Frebourg; Jean Michon; Stanislas Lyonnet; Jeanne Amiel; Olivier Delattre
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

Review 7.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

8.  Identification of ALK as a major familial neuroblastoma predisposition gene.

Authors:  Yaël P Mossé; Marci Laudenslager; Luca Longo; Kristina A Cole; Andrew Wood; Edward F Attiyeh; Michael J Laquaglia; Rachel Sennett; Jill E Lynch; Patrizia Perri; Geneviève Laureys; Frank Speleman; Cecilia Kim; Cuiping Hou; Hakon Hakonarson; Ali Torkamani; Nicholas J Schork; Garrett M Brodeur; Gian P Tonini; Eric Rappaport; Marcella Devoto; John M Maris
Journal:  Nature       Date:  2008-08-24       Impact factor: 49.962

9.  Identification of ALK in Thinness.

Authors:  Michael Orthofer; Armand Valsesia; Reedik Mägi; Qiao-Ping Wang; Joanna Kaczanowska; Ivona Kozieradzki; Alexandra Leopoldi; Domagoj Cikes; Lydia M Zopf; Evgenii O Tretiakov; Egon Demetz; Richard Hilbe; Anna Boehm; Melita Ticevic; Margit Nõukas; Alexander Jais; Katrin Spirk; Teleri Clark; Sabine Amann; Maarja Lepamets; Christoph Neumayr; Cosmas Arnold; Zhengchao Dou; Volker Kuhn; Maria Novatchkova; Shane J F Cronin; Uwe J F Tietge; Simone Müller; J Andrew Pospisilik; Vanja Nagy; Chi-Chung Hui; Jelena Lazovic; Harald Esterbauer; Astrid Hagelkruys; Ivan Tancevski; Florian W Kiefer; Tibor Harkany; Wulf Haubensak; G Gregory Neely; Andres Metspalu; Jorg Hager; Nele Gheldof; Josef M Penninger
Journal:  Cell       Date:  2020-05-21       Impact factor: 41.582

10.  Activating mutations in ALK provide a therapeutic target in neuroblastoma.

Authors:  Rani E George; Takaomi Sanda; Megan Hanna; Stefan Fröhling; William Luther; Jianming Zhang; Yebin Ahn; Wenjun Zhou; Wendy B London; Patrick McGrady; Liquan Xue; Sergey Zozulya; Vlad E Gregor; Thomas R Webb; Nathanael S Gray; D Gary Gilliland; Lisa Diller; Heidi Greulich; Stephan W Morris; Matthew Meyerson; A Thomas Look
Journal:  Nature       Date:  2008-10-16       Impact factor: 49.962

View more
  2 in total

1.  A hypothalamic pathway for Augmentor α-controlled body weight regulation.

Authors:  Mansoor Ahmed; Navjot Kaur; Qianni Cheng; Marya Shanabrough; Evgenii O Tretiakov; Tibor Harkany; Tamas L Horvath; Joseph Schlessinger
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-11       Impact factor: 12.779

Review 2.  Anaplastic lymphoma kinase-special immunity and immunotherapy.

Authors:  Ye Guo; Hanfei Guo; Yongfei Zhang; Jiuwei Cui
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.